1
|
Scailteux L, Despas F, Balusson F, Campillo-Gimenez B, Mathieu R, Vincendeau S, Happe A, Nowak E, Kerbrat S, Oger E. Hospitalisation pour évènements indésirables sous abiratérone ou enzalutamide chez des patients avec cancer de prostate résistant à la castration : étude française sur base de données médico-administratives. Prog Urol 2021. [DOI: 10.1016/j.purol.2021.08.062] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
2
|
Lamy S, Colineaux H, Grosclaude P, Despas F, Laurent G, Delpierre C, Lepage B. Les mécanismes d’influence de la comorbidité sur la survie des patients traités pour un lymphome B diffus à grandes cellules dépendent-ils du lieu de traitement ? Une étude en présence de médiateurs multiples causalement ordonnés. Rev Epidemiol Sante Publique 2020. [DOI: 10.1016/j.respe.2020.03.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
3
|
Vayr F, Conte C, Despas F, Gauthier M, Soulat JM, Lapeyre Mestre M, Herin F. Impact de la prise en charge de la leucémie myéloïde chronique par les médicaments inhibiteurs des protéines kinases sur l’activité professionnelle : analyse à partir du Système national des données de santé. ARCH MAL PROF ENVIRO 2020. [DOI: 10.1016/j.admp.2019.12.017] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
4
|
Montastruc G, Despas F, Rousseau V, Lafaurie M, De Canecaude C, Durrieu G, Montastruc F, Bagheri H, Montastruc J. Lipid-lowering drugs and the risk of cataract: An Observational Post Marketing Study. Archives of Cardiovascular Diseases Supplements 2020. [DOI: 10.1016/j.acvdsp.2019.09.419] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
5
|
Koffi KG, Silué DA, Laurent C, Boidy K, Koui S, Compaci G, Adeba ZH, Kamara I, Botty RP, Bognini AS, Sanogo I, Despas F, Laurent G. AMAFRICA, a patient-navigator program for accompanying lymphoma patients during chemotherapy in Ivory Coast: a prospective randomized study. BMC Cancer 2019; 19:1247. [PMID: 31870438 PMCID: PMC6929302 DOI: 10.1186/s12885-019-6478-3] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/18/2019] [Accepted: 12/17/2019] [Indexed: 01/08/2023] Open
Abstract
Background Previous studies have indicated that accompanying socially underserved cancer patients through Patient Navigator (PN) or PN-derived procedures improves therapy management and reassurance. At the Cancer Institute of Toulouse-Oncopole (France), we have implemented AMA (Ambulatory Medical Assistance), a PN-based procedure adapted for malignant lymphoma (ML) patients under therapy. We found that AMA improves adherence to chemotherapy and safety. In low-middle income countries (LMIC), refusal and abandonment were documented as major adverse factors for cancer therapy. We reasoned that AMA could improve clinical management of ML patients in LMIC. Methods This study was set up in the Abidjan University Medical Center (Ivory Coast) in collaboration with Toulouse. One hundred African patients were randomly assigned to either an AMA or control group. Main criteria of judgment were refusal and abandonment of CHOP or ABVD chemotherapy. Results We found that AMA was feasible and had significant impact on refusal and abandonment. However, only one third of patients completed their therapy in both groups. No differences were noted in terms of complete response rate (CR) (16% based on intent-to-treat) and median overall survival (OS) (6 months). The main reason for refusal and abandonment was limitation of financial resources. Conclusion Altogether, this study showed that PN may reduce refusal and abandonment of treatment. However, due to insufficient health care coverage, its ultimate impact on OS remains limited.
Collapse
Affiliation(s)
- K G Koffi
- Hematology Teaching Hospital of Yopougon University Medical Center, Abidjan, Côte d'Ivoire.
| | - D A Silué
- Hematology Teaching Hospital of Yopougon University Medical Center, Abidjan, Côte d'Ivoire
| | - C Laurent
- Hematology Department of Toulouse University Medical Center, Toulouse, France
| | - K Boidy
- Hematology Teaching Hospital of Yopougon University Medical Center, Abidjan, Côte d'Ivoire
| | - S Koui
- Hematology Teaching Hospital of Yopougon University Medical Center, Abidjan, Côte d'Ivoire
| | - G Compaci
- Hematology Department of Toulouse University Medical Center, Toulouse, France
| | - Z H Adeba
- Hematology Teaching Hospital of Yopougon University Medical Center, Abidjan, Côte d'Ivoire
| | - I Kamara
- Hematology Teaching Hospital of Yopougon University Medical Center, Abidjan, Côte d'Ivoire
| | - R P Botty
- Hematology Teaching Hospital of Yopougon University Medical Center, Abidjan, Côte d'Ivoire
| | - A S Bognini
- Hematology Teaching Hospital of Yopougon University Medical Center, Abidjan, Côte d'Ivoire
| | - I Sanogo
- Hematology Teaching Hospital of Yopougon University Medical Center, Abidjan, Côte d'Ivoire
| | - F Despas
- Hematology Department of Toulouse University Medical Center, Toulouse, France
| | - G Laurent
- Hematology Department of Toulouse University Medical Center, Toulouse, France
| |
Collapse
|
6
|
Scailteux L, Campillo-Gimenez B, Kerbrat S, Despas F, Mathieu R, Vincendeau S, Balusson F, Happe A, Nowak E, Oger E. Survie globale des patients français traités par abiraterone et enzalutamide pour un cancer de prostate résistant à la castration chimio-naïfs entre 2014 et 2017 : une comparaison directe à travers une étude sur base de données médico-administratives. Prog Urol 2019. [DOI: 10.1016/j.purol.2019.08.140] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
7
|
Scailteux L, Campillo-Gimenez B, Kerbrat S, Despas F, Mathieu R, Vincendeau S, Balusson F, Happe A, Nowak E, Oger E. Survie globale des patients français traités par abiraterone et enzalutamide pour un cancer de prostate résistant à la castration en échec de chimiothérapie entre 2014 et 2017 : une comparaison directe à travers une étude sur base de données médico-administratives. Prog Urol 2019. [DOI: 10.1016/j.purol.2019.08.143] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
8
|
Walburg V, Rueter M, Lamy S, Compaci G, Lapeyre-Mestre M, Laurent G, Despas F. Fear of cancer recurrence in Non- and Hodgkin lymphoma survivors during their first three years of survivorship among French patients. PSYCHOL HEALTH MED 2019; 24:781-787. [PMID: 30714815 DOI: 10.1080/13548506.2019.1574354] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Abstract
The aim of this study was to measure the prevalence of FCR among a sample of French lymphoma survivors and to determine factors associated with clinical levels of FCR. The study was conducted with two cross-sectional measures: sociodemographic and anxiety, depression as well as health-related quality of life (HRQoL) scores were measured at the baseline of the post-cancer period and FCR was evaluated during the first 3 years of survivorship. The prevalence of clinical levels of FCR (≥13) was evaluated by the Fear of Cancer Recurrence Inventory - Short Form (FCRI-SF) among non- and Hodgkin lymphoma survivors undergoing prior first-line chemotherapy. Among 108 lymphoma survivors with an average follow-up of 1.6 years (range 0.3-3.0 years), clinical levels of FCR (≥13) were observed for 44.4% (n = 48). Multivariate analysis indicated that baseline anxiety and low quality of life were related to clinically significant FCR levels.
Collapse
Affiliation(s)
- V Walburg
- a Faculty of Literature and Human Sciences , Catholic Institute of Toulouse , Toulouse , France
| | - M Rueter
- b Service of Medical and Clinical Pharmacology, Center of Pharmacovigilance, Pharmaco-epidemiology and Information on Drugs , Toulouse University Hospital , Toulouse , France.,c Faculty of Medicine , INSERM Unit 1027 (French National Institute of Health and Medical Research) , Toulouse , France
| | - S Lamy
- b Service of Medical and Clinical Pharmacology, Center of Pharmacovigilance, Pharmaco-epidemiology and Information on Drugs , Toulouse University Hospital , Toulouse , France.,c Faculty of Medicine , INSERM Unit 1027 (French National Institute of Health and Medical Research) , Toulouse , France.,d Department of Epidemiology, Health Economics and Public Health, Faculty of Medicine , University of Toulouse III Paul Sabatier , Toulouse , France
| | - G Compaci
- e Department of Hematology-Internal Medicine , Toulouse University Hospital, Cancer University Institute of Toulouse Oncopole , Toulouse , France
| | - M Lapeyre-Mestre
- b Service of Medical and Clinical Pharmacology, Center of Pharmacovigilance, Pharmaco-epidemiology and Information on Drugs , Toulouse University Hospital , Toulouse , France.,c Faculty of Medicine , INSERM Unit 1027 (French National Institute of Health and Medical Research) , Toulouse , France.,f Laboratory of Medical and Clinical Pharmacology Faculty of Medicine , University III Paul Sabatier , Toulouse , France.,g INSERM CIC 1436, Clinical Investigation Center , Toulouse University Hospital , Toulouse , France
| | - G Laurent
- c Faculty of Medicine , INSERM Unit 1027 (French National Institute of Health and Medical Research) , Toulouse , France.,e Department of Hematology-Internal Medicine , Toulouse University Hospital, Cancer University Institute of Toulouse Oncopole , Toulouse , France
| | - F Despas
- b Service of Medical and Clinical Pharmacology, Center of Pharmacovigilance, Pharmaco-epidemiology and Information on Drugs , Toulouse University Hospital , Toulouse , France.,c Faculty of Medicine , INSERM Unit 1027 (French National Institute of Health and Medical Research) , Toulouse , France.,f Laboratory of Medical and Clinical Pharmacology Faculty of Medicine , University III Paul Sabatier , Toulouse , France.,g INSERM CIC 1436, Clinical Investigation Center , Toulouse University Hospital , Toulouse , France
| |
Collapse
|
9
|
Berger E, Delpierre C, Despas F, Berard E, Recher C, Lamy S. Do patients’ SEP influence therapeutic strategy in acute myeloid leukaemia: Results from a French longitudinal observational study. Rev Epidemiol Sante Publique 2018. [DOI: 10.1016/j.respe.2018.05.336] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022] Open
|
10
|
Lamy S, Grosclaude P, Despas F, Laurent G, Lepage B, Delpierre C. Effect modification of the treatment efficacy by comorbidity using “real-life” data from a French cohort of patients treated for DLBCL. Rev Epidemiol Sante Publique 2018. [DOI: 10.1016/j.respe.2018.05.501] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022] Open
|
11
|
Berger E, Delpierre C, Despas F, Berard E, Bories P, Sarry A, Recher C, Lamy S. La position sociale influence-t-elle le choix du traitement dans la leucémie aiguë myéloïde du sujet âgé ? Une étude longitudinale en Midi-Pyrénées (France). Rev Epidemiol Sante Publique 2018. [DOI: 10.1016/j.respe.2018.03.321] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
12
|
Lamy S, Grosclaude P, Despas F, Laurent G, Lepage B, Delpierre C. Effet modificateur de la comorbidité sur l’efficacité de la chimiothérapie : une étude observationnelle chez des patients traités pour un lymphome B diffus à grandes cellules en Midi-Pyrénées. Rev Epidemiol Sante Publique 2018. [DOI: 10.1016/j.respe.2018.03.363] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022] Open
|
13
|
Bondon-Guitton E, Combret S, Pérault-Pochat MC, Stève-Dumont M, Bagheri H, Huguet F, Despas F, Pathak A, Montastruc JL. Cardiovascular risk profile of patients with peripheral arterial occlusive disease during nilotinib therapy. Target Oncol 2017; 11:549-52. [PMID: 26891968 DOI: 10.1007/s11523-016-0417-x] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
BACKGROUND Over the past few years, data have suggested that severe peripheral arterial occlusive disease (PAOD) is associated with nilotinib exposure. However, the characteristics of this adverse drug reaction are poorly described since its frequency is low. As far as we know, no study using a spontaneous adverse drug reactions reporting system was performed to describe the characteristics of cases of PAOD related to nilotinib. OBJECTIVE We performed a study to describe the cardiovascular risk profile of cases of PAOD in patients treated with nilotinib spontaneously reported to the French Pharmacovigilance Database (FPVD). PATIENTS/METHODS We selected all cases of "vascular disorders," as the System Organ Class in MedDRA®, in which nilotinib was "suspected" and recorded in the French Pharmacovigilance Database between 2007 and 21 October 2014. We then identified cases of PAOD with a Low Level Term and through a detailed summary of the clinical description. RESULTS We identified 25 cases of POAD. Most of the patients were older than 60 years (84 %) or had another cardiovascular risk factor such as hypercholesterolemia, arterial hypertension, overweight/obesity, smoking, or diabetes mellitus (72 %). Females (13 cases) and males (12 cases) were equally represented, but the presence of cardiovascular risk factors was more frequent in females than in males. The mean time from initiation of nilotinib to PAOD onset was 24 months and was significantly longer in patients aged less than 60 years compared with those aged over 60 years (33.8 ± 24.6 months vs. 22.6 ± 17.5 months, p = 0.002). Pre-existing cardiovascular risk factors, especially diabetes mellitus, also seem to accelerate its occurrence. CONCLUSIONS The FPVD is a useful tool in describing the cardiovascular risk profile of patients with PAOD during nilotinib exposure. Physicians have to be particularly vigilant in patients older than 60 years of age; in patients younger than 60 years of age, long-term surveillance has to be maintained.
Collapse
Affiliation(s)
- E Bondon-Guitton
- Service de Pharmacologie Médicale et Clinique, Centre Midi-Pyrénées de Pharmacovigilance, Pharmacoépidémiologie et Informations sur le Médicament, Pharmacopôle Midi-Pyrénées, CHU Toulouse, Faculté de Médecine de l'Université de Toulouse, Toulouse, France.
| | - S Combret
- Centre Régional de Pharmacovigilance de Bourgogne, Centre Hospitalier Universitaire, Dijon, France
| | - M C Pérault-Pochat
- Pharmacologie Clinique et Vigilances, Centre Hospitalier Universitaire, Poitiers, France
| | - M Stève-Dumont
- Centre Régional de Pharmacovigilance, Hôpital de Cimiez, Nice, France
| | - H Bagheri
- Service de Pharmacologie Médicale et Clinique, Centre Midi-Pyrénées de Pharmacovigilance, Pharmacoépidémiologie et Informations sur le Médicament, Pharmacopôle Midi-Pyrénées, CHU Toulouse, Faculté de Médecine de l'Université de Toulouse, Toulouse, France
| | - F Huguet
- Service d'Hématologie, Institut Universitaire du Cancer, Toulouse, France
| | - F Despas
- Service de Pharmacologie Médicale et Clinique, CHU Toulouse, Faculté de Médecine de l'Université de Toulouse, Toulouse, France
| | - A Pathak
- Service de Pharmacologie Médicale et Clinique, CHU Toulouse, Faculté de Médecine de l'Université de Toulouse, Toulouse, France
| | - J L Montastruc
- Service de Pharmacologie Médicale et Clinique, Centre Midi-Pyrénées de Pharmacovigilance, Pharmacoépidémiologie et Informations sur le Médicament, Pharmacopôle Midi-Pyrénées, CHU Toulouse, Faculté de Médecine de l'Université de Toulouse, Toulouse, France
| |
Collapse
|
14
|
de Campaigno EP, Kebir I, Lapeyre-Mestre M, Montastruc J, Despas F. Drug-Induced Dental Caries, Lessons from a Disproportionality Analysis in Vigibase®: Beware of Bisphosphonates, Atropinic, Immunosuppressant and Hyperglycaemic Drugs. Clin Ther 2017. [DOI: 10.1016/j.clinthera.2017.05.129] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
15
|
Conte C, Palmaro A, Costa N, Despas F, Grosclaude P, Lapeyre-Mestre M. Evaluation of algorithms to identify incident lymphoma cases using claims databases with cancer registry. Rev Epidemiol Sante Publique 2017. [DOI: 10.1016/j.respe.2017.03.059] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
16
|
Palmaro A, Patras de Campaigno E, Dupui M, Barricault B, Despas F, Lapeyre-Mestre M. Analyse de données longitudinales pour la production d’indicateurs automatisés sur les interactions médicamenteuses potentielles : application aux bases de données de l’Assurance maladie. Rev Epidemiol Sante Publique 2017. [DOI: 10.1016/j.respe.2017.01.024] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
17
|
Lamy S, Bettiol C, Grosclaude P, Compaci G, Albertus G, Récher C, Nogaro JC, Despas F, Laurent G, Delpierre C. The care center influences the management of lymphoma patients in a universal health care system: an observational cohort study. BMC Health Serv Res 2016; 16:336. [PMID: 27485349 PMCID: PMC4969648 DOI: 10.1186/s12913-016-1553-9] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/12/2016] [Accepted: 07/12/2016] [Indexed: 02/07/2023] Open
Abstract
Background Healthcare providers-related disparities in adherence to the treatment plan among lymphoma patients are found even in a universal healthcare system, but the mechanism remains unclear. We investigated the association between the type of care center and the relative dose intensity and determined whether it persists after adjustment for patients’ recruitment differences. Methods Prospective observational cohort study of 294 patients treated with standard protocols for diffuse large B-cell lymphoma (DLBCL) in teaching or community public hospitals or in private centers in the French Midi-Pyrénées region from 2006–2013. To test our assumptions, we used multinomial and mixed-effect logistic models progressively adjusted for patients’ biomedical characteristics, socio-spatial characteristics and treatment-related toxicity events. Results Patients treated using standard protocols in the teaching hospital had more advanced stage and poorer initial prognosis without limitation regarding the distance from the residence to the care center. Patients’ recruitment profile across the different types of care center failed to explain the difference in relative dose intensity. Low relative dose intensity was less often observed in teaching hospital than elsewhere. Conclusion We showed that even in a universal healthcare system, disparities in the management of DLBCL patients’ do exist according to the types of care center. A main issue may be to find and diffuse the reasons of this benefit in cancer management in the teaching hospital to the other centers.
Collapse
Affiliation(s)
- S Lamy
- University of Toulouse III Paul Sabatier, Toulouse, France. .,Department of Clinical Pharmacology, Toulouse University Hospital, Toulouse, France. .,INSERM UMR1027 (The French National Institute of Health and Medical Research), Toulouse, France.
| | - C Bettiol
- Department of Hematology, Toulouse University Hospital, Toulouse University Cancer Institute (IUCT-O), Toulouse, France
| | - P Grosclaude
- INSERM UMR1027 (The French National Institute of Health and Medical Research), Toulouse, France.,Tarn Cancers Registry, Albi, France
| | - G Compaci
- Department of Hematology, Toulouse University Hospital, Toulouse University Cancer Institute (IUCT-O), Toulouse, France
| | - G Albertus
- INSERM UMR1027 (The French National Institute of Health and Medical Research), Toulouse, France
| | - C Récher
- University of Toulouse III Paul Sabatier, Toulouse, France.,Department of Hematology, Toulouse University Hospital, Toulouse University Cancer Institute (IUCT-O), Toulouse, France.,INSERM UMR1037 (The French National Institute of Health and Medical Research), Cancer Research Center of Toulouse, Toulouse, France
| | - J C Nogaro
- Department of Hematology, Toulouse University Hospital, Toulouse University Cancer Institute (IUCT-O), Toulouse, France
| | - F Despas
- University of Toulouse III Paul Sabatier, Toulouse, France.,Department of Clinical Pharmacology, Toulouse University Hospital, Toulouse, France.,INSERM UMR1027 (The French National Institute of Health and Medical Research), Toulouse, France
| | - G Laurent
- University of Toulouse III Paul Sabatier, Toulouse, France.,Department of Hematology, Toulouse University Hospital, Toulouse University Cancer Institute (IUCT-O), Toulouse, France.,INSERM UMR1037 (The French National Institute of Health and Medical Research), Cancer Research Center of Toulouse, Toulouse, France
| | - C Delpierre
- INSERM UMR1027 (The French National Institute of Health and Medical Research), Toulouse, France
| |
Collapse
|
18
|
Lamy S, Albertus G, Grosclaude P, Bettiol C, Compaci G, Récher C, Nogaro JC, Despas F, Laurent G, Delpierre C. Étude de l’effet du centre de traitement sur l’adhésion au plan de traitement dans le lymphome B diffus à grandes cellules : une analyse multiniveau d’une cohorte observationnelle en région Midi-Pyrénées en onco-hématologie. Rev Epidemiol Sante Publique 2016. [DOI: 10.1016/j.respe.2016.03.090] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
19
|
Tournaire G, Despas F, Huguet F, Montastruc JL, Bondon-Guitton E. Peripheral arterial occlusive disease during ponatinib therapy after failure of imatinib: a case report. J Clin Pharm Ther 2016; 41:360-361. [PMID: 27009771 DOI: 10.1111/jcpt.12383] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/16/2016] [Accepted: 03/01/2016] [Indexed: 12/01/2022]
Abstract
WHAT IS KNOWN AND OBJECTIVE Peripheral vascular adverse events have been reported with ponatinib treatment in chronic myeloid leukaemia (CML) after failure of dasatinib or nilotinib. We here report peripheral arterial occlusive disease (PAOD) in a patient who had previously received only imatinib as tyrosine kinase inhibitor. CASE DESCRIPTION The patient was a 70-year-old man with no history of cardiovascular disease. He developed arterial hypertension 5 months after the initiation of ponatinib and PAOD 41 months later. WHAT IS NEW AND CONCLUSION Peripheral arterial occlusive disease can occur several years after the initiation of ponatinib in patients who had previously received only imatinib. Long-term surveillance is required for preventing the complications of ponatinib-associated PAOD.
Collapse
Affiliation(s)
- G Tournaire
- Service de Pharmacologie Médicale et Clinique, Centre Midi-Pyrénées de Pharmacovigilance, Pharmacoépidémiologie et Informations sur le Médicament, Pharmacopôle Midi-Pyrénées, Faculté de Médecine de l'Université de Toulouse, Centre Hospitalier Universitaire de Toulouse, Toulouse, France
| | - F Despas
- Service de Pharmacologie Médicale et Clinique, Faculté de Médecine de l'Université de Toulouse, Centre Hospitalier Universitaire de Toulouse, Toulouse, France
| | - F Huguet
- Service d'Hématologie, Institut Universitaire du Cancer, Toulouse, France
| | - J L Montastruc
- Service de Pharmacologie Médicale et Clinique, Centre Midi-Pyrénées de Pharmacovigilance, Pharmacoépidémiologie et Informations sur le Médicament, Pharmacopôle Midi-Pyrénées, Faculté de Médecine de l'Université de Toulouse, Centre Hospitalier Universitaire de Toulouse, Toulouse, France
| | - E Bondon-Guitton
- Service de Pharmacologie Médicale et Clinique, Centre Midi-Pyrénées de Pharmacovigilance, Pharmacoépidémiologie et Informations sur le Médicament, Pharmacopôle Midi-Pyrénées, Faculté de Médecine de l'Université de Toulouse, Centre Hospitalier Universitaire de Toulouse, Toulouse, France
| |
Collapse
|
20
|
Palmaro A, Gauthier M, Despas F, Lapeyre-Mestre M. Reconstituer les lignes de traitement reçues en onco-hématologie à partir des données du Sniiram et du PMSI : application à l’étude des cycles de chimiothérapie dans le myélome multiple. Rev Epidemiol Sante Publique 2016. [DOI: 10.1016/j.respe.2016.01.040] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
21
|
Palmaro A, Despas F, Lapeyre-Mestre M. Thomboprophylaxis In Multiple Myeloma Patients Treated With Lenalidomide or Thalidomide. Clin Ther 2015. [DOI: 10.1016/j.clinthera.2015.05.195] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
22
|
Pathak A, Lebrin M, Vaccaro A, Senard JM, Despas F. Pharmacology of levosimendan: inotropic, vasodilatory and cardioprotective effects. J Clin Pharm Ther 2013; 38:341-9. [PMID: 23594161 DOI: 10.1111/jcpt.12067] [Citation(s) in RCA: 74] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/05/2012] [Accepted: 03/20/2013] [Indexed: 01/15/2023]
Abstract
WHAT IS KNOWN AND OBJECTIVE Positive inotropic agents are frequently used in acute decompensated heart failure (ADHF) due to left ventricular systolic dysfunction. These agents are known to improve cardiac performance and peripheral perfusion in the short-term treatment. However, several preclinical and clinical studies emphasized detrimental effects of these drugs on myocardial oxygen demand and on sympathetic tone entailing arrhythmogenesis. Levosimendan is an inotropic agent with an original mechanism of action. This review focuses on major data available for levosimendan. METHODS A literature search was conducted in the PubMed database by including studies published in English using combinations of the following key words, levosimendan, inotropic drugs and acute heart failure. Furthermore, bibliographies of selected references were also evaluated for relevant articles. The collection for this review was limited to the most recently available human and animal data. RESULTS AND DISCUSSION Levosimendan's vasodilatory and cardioprotective effects are mediated by calcium sensitization of contractile proteins and opening of adenosine triphosphate (ATP)-dependent K+ channels in vascular smooth muscle cells and on mitochondrial ATP-sensitive potassium [mito.K(ATP)] channels. This inotropic agent has mild PDE inhibitory action. Unlike other inotropic agents, levosimendan improves cardiac performance without activating the sympathetic nervous system. Moreover, there are evidences that levosimendan has additional anti-inflammatory and anti-apoptotic properties that prevent cardiac toxicity and contributes to positive hemodynamic response of the drug. Four randomized trials evaluated the effects of levosimendan on mortality in patients with acute decompensated chronic heart failure; nevertheless, a clear benefit has not been demonstrated so far. Although levosimendan is indicated for the treatment of ADHF (class of recommendation IIa, level of evidence B), it is has not been approved in all countries. WHAT IS NEW AND CONCLUSION This review summarizes the characteristics and the current knowledge of the literature on levosimendan and its active metabolite OR-1896.
Collapse
Affiliation(s)
- A Pathak
- Institut National de Sante et de Recherche Médicale (INSERM), UMR-1048, Institut des maladies métaboliques et cardiovasculaires I2MC, Toulouse, France
| | | | | | | | | |
Collapse
|
23
|
Franchitto N, Despas F, Labrunee M, Boveda S, Galinier M, Senard JM, Pathak A. EXCESSIVE SYMPATHETIC ACTIVATION IN HEART FAILURE ASSOCIATED WITH ANEMIA: PP.32.260. J Hypertens 2010. [DOI: 10.1097/01.hjh.0000379798.77141.d6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
24
|
Guilbeau-Frugier C, Honton B, Despas F, Genet G, Pathak A, Galés C, Senard J. P3.10 Chemical denervation of sympathetic nervous system induces abnormal myocardial architecture. Auton Neurosci 2009. [DOI: 10.1016/j.autneu.2009.05.158] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
25
|
Despas F, Trouillet C, Franchitto N, Galinier M, Senard J, Pathak A. P1.15 Levosimedan improves hemodynamics functions without sympathetic activation in severe heart failure patients refractory to dobutamine: Direct evidence from sympathetic neural recording. Auton Neurosci 2009. [DOI: 10.1016/j.autneu.2009.05.111] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
26
|
Despas F, Detis N, Franchitto N, Galinier M, Senard JM, Pathak A. P1.14 Excessive sympathetic activation in heart failure with chronic renal failure: Role of chemoreflex activation. Auton Neurosci 2009. [DOI: 10.1016/j.autneu.2009.05.110] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
27
|
Despas F, Serrand J, Franchitto N, Labrunee M, Soussan M, Honton B, Galinier M, Senard JM, Pathak A. H011 Aortic valve remplacement normalizes sympathetic nerve activity in patient with severe aorticv stenosis. Arch Cardiovasc Dis 2009. [DOI: 10.1016/s1875-2136(09)72310-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
28
|
Despas F, Fruit D, Baixas C, Castel M, Alquier C, Galinier M, Senard JM, Pathak A. H012 QT dynamicity predicts short term mortality in acute heart failure patient. Arch Cardiovasc Dis 2009. [DOI: 10.1016/s1875-2136(09)72311-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
29
|
Genet G, Guilbeau-Frugier C, Despas F, Arvanitis D, Honton B, Altie MF, Davy A, Pathak A, Senard JM, Gales C. H030 Loss of Ephrin-B1 disrupts myocardial architecture and leads to abnormal sympathetic heart rate variability. Arch Cardiovasc Dis 2009. [DOI: 10.1016/s1875-2136(09)72329-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|